Company / Free Cash Flow
Travere Therapeutics, Inc. Free Cash Flow History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$280.7M
FY2023
5-year range
-$280.7M / -$58.4M
FY2019-FY2023
Trend
-50.5%
vs FY2022
Sector context
#167 of 194
Health Care
What the data says
Travere Therapeutics, Inc.'s free cash flow of -$281M is lower than 86% of companies in the Health Care sector (FY2023). Free Cash Flow has declined for 4 consecutive years, from $7M in FY2019 to -$281M in FY2023.
Based on SEC 10-K filings.
-$281M in FY2023.
Declined from -$58M to -$281M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 14% in Health CareTop 86% of 194This company -$280.7M Sector average $470.6M
▼
-159.6% below sector average
Key checks
Key Insights
- Travere Therapeutics, Inc.'s free cash flow has declined for 4 consecutive years.
- In FY2023, free cash flow decreased 50.5% year-over-year.
- Ranks #167 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | -$280.7M | -50.5% |
| FY2022 | -$186.5M | -219.3% |
| FY2021 | -$58.4M | -127.4% |
| FY2020 | -$25.7M | -494.2% |
| FY2019 | $6.5M | +233.8% |
| FY2018 | -$4.9M | -245.1% |
| FY2017 | -$1.4M | +97.0% |
| FY2016 | -$46.5M | -3196.5% |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026